|
1
|
He J, Gu D, Wu X, Reynolds K, Duan X, Yao
C, Wang J, Chen CS, Chen J, Wildman RP, Klag MJ and Whelton PK:
Major causes of death among men and women in China. N Engl J Med.
353:1124–1134. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fukata M and Abreu MT: Pathogen
recognition receptors, cancer and inflammation in the gut. Curr
Opin Pharmacol. 9:680–687. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takeda K and Akira S: Microbial
recognition by Toll-like receptors. J Dermatol Sci. 34:73–82. 2004.
View Article : Google Scholar
|
|
4
|
Underhill DM: Toll-like receptors:
networking for success. Eur J Immunol. 33:1767–1775. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barton GM and Medzhitov R: Toll-like
receptor signaling pathways. Science. 300:1524–1525. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
|
|
7
|
Wagner H: The immunobiology of the TLR9
subfamily. Trends Immunol. 25:381–386. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa
T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander
KS: Toll-like receptor 9 agonists promote cellular invasion by
increasing matrix metalloproteinase activity. Mol Cancer Res.
4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger R, Fiegl H, Goebel G, Obexer P,
Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle
D, Reimer D, Müller-Holzner E, Jones A and Widschwendter M:
Toll-like receptor 9 expression in breast and ovarian cancer is
associated with poorly differentiated tumors. Cancer Sci.
101:1059–1066. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ilvesaro JM, Merrell MA, Swain TM,
Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like
receptor-9 agonists stimulate prostate cancer invasion in vitro.
Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang
Y, Zhou Y, Zhou H and Wen Z: Tlr9 signaling promotes tumor
progression of human lung cancer cell in vivo. Pathol Oncol Res.
15:623–630. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka J, Sugimoto K, Shiraki K, Tameda M,
Kusagawa S, Nojiri K, Beppu T, Yoneda K, Yamamoto N, Uchida K,
Kojima T and Takei Y: Functional cell surface expression of
toll-like receptor 9 promotes cell proliferation and survival in
human hepatocellular carcinomas. Int J Oncol. 37:805–814.
2010.PubMed/NCBI
|
|
13
|
Wang C, Cao S, Yan Y, Ying Q, Jiang T, Xu
K and Wu A: TLR9 expression in glioma tissues correlated to glioma
progression and the prognosis of GBM patients. BMC Cancer.
10:415–426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jukkola-Vuorinen A, Rahko E, Vuopala KS,
Desmond R, Lehenkari PP, Harris KW and Selander KS: Toll-like
receptor-9 expression is inversely correlated with estrogen
receptor status in breast cancer. J Innate Immun. 1:59–68. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
González-Reyes S, Marín L, González L,
González LO, del Casar JM, Lamelas ML, González-Quintana JM and
Vizoso FJ: Study of TLR3, TLR4 and TLR9 in breast carcinomas and
their association with metastasis. BMC Cancer. 10:665–673.
2010.PubMed/NCBI
|
|
16
|
Wu HQ, Wang B, Zhu SK, Tian Y, Zhang JH
and Wu HS: Effects of CPG ODN on biological behavior of PANC-1 and
expression of TLR9 in pancreatic cancer. World J Gastroenterol.
17:996–1003. 2011.PubMed/NCBI
|
|
17
|
Droemann D, Albrecht D, Gerdes J, Ulmer
AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P and Goldmann T:
Human lung cancer cells express functionally active Toll-like
receptor 9. Respir Res. 6:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zeromski J, Mozer-Lisewska I and Kaczmarek
M: Significance of Toll-like receptors expression in tumor growth
and spreading: a short review. Cancer Microenviron. 1:37–42. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jurk M and Vollmer J: Therapeutic
applications of synthetic CpG oligodeoxynucleotides as TLR9
agonists for immune modulation. BioDrugs. 21:387–401. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hemmi H, Takeuchi O, Kawai T, Kaisho T,
Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and
Akira S: A Toll-like receptor recognizes bacterial DNA. Nature.
408:740–745. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeshita F, Gursel I, Ishii KJ, Suzuki K,
Gursel M and Klinman DM: Signal transduction pathways mediated by
the interaction of CpG DNA with Toll-like receptor 9. Semin
Immunol. 16:17–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuo CC, Kuo CW, Liang CM and Liang SM: A
transcriptomic and proteomic analysis of the effect of CpG-ODN on
human THP-1 monocytic leukemia cells. Proteomics. 5:894–906. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kostjuk S, Loseva P, Chvartatskaya O,
Ershova E, Smirnova T, Malinovskaya E, Roginko O, Kuzmin V,
Izhevskaia V, Baranova A, Ginter E and Veiko N: Extracellular
GC-rich DNA activates TLR9- and NF-κB-dependent signaling pathways
in human adipose-derived mesenchymal stem cells (haMSCs). Expert
Opin Biol Ther. 12(Suppl 1): S99–S111. 2012.PubMed/NCBI
|
|
24
|
Zhao H, Dong Y, Tian X, Tan TK, Liu Z,
Zhao Y, Zhang Y, Harris DCh and Zheng G: Matrix metalloproteinases
contribute to kidney fibrosis in chronic kidney diseases. World J
Nephrol. 2:84–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folgueras AR, Pendas AM, Sanchez LM and
Lopez-Otin C: Matrix metalloproteinases in cancer: from new
functions to improved inhibition strategies. Int J Dev Biol.
48:411–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng ZS, Cohen AM and Guillem JG: Loss of
basement membrane type IV collagen is associated with increased
expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during
human colorectal tumorigenesis. Carcinogenesis. 20:749–755. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bartsch JE, Staren ED and Appert HE:
Matrix metalloproteinase expression in breast cancer. J Surg Res.
110:383–392. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jezierska A and Motyl T: Matrix
metalloproteinase-2 involvement in breast cancer progression: a
mini-review. Med Sci Monit. 15:RA32–RA40. 2009.PubMed/NCBI
|
|
29
|
Sims JD, McCready J and Jay DG:
Extracellular heat shock protein (Hsp)70 and Hsp90 alpha assist in
matrix metalloproteinase-2 activation and breast cancer cell
migration and invasion. PLoS One. 6:e188482011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee KH, Shin SJ, Kim KO, Kim MK, Hyun MS,
Kim TN, Jang BI, Kim SW, Song SK, Kim HS, Bae SH and Ryoo HM:
Relationship between E-cadherin, matrix metalloproteinase-7 gene
expression and clinicopathological features in gastric carcinoma.
Oncol Rep. 16:823–830. 2006.PubMed/NCBI
|
|
31
|
Okayama H, Kumamoto K, Saitou K, Hayase S,
Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Sekikawa K and
Takenoshita S: CD44v6, MMP-7 and nuclear Cdx2 are significant
biomarkers for prediction of lymph node metastasis in primary
gastric cancer. Oncol Rep. 22:745–755. 2009.PubMed/NCBI
|
|
32
|
Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang
HB and Wu JJ: Elevated serum matrix metalloproteinase-3 and -7 in
H. pylori-related gastric cancer can be biomarkers
correlating with a poor survival. Dig Dis Sci. 55:1649–1657.
2010.PubMed/NCBI
|
|
33
|
Sugie S, Tsukino H, Mukai S, Akioka T,
Shibata N, Nagano M and Kamoto T: Cyclooxygenase 2 genotypes
influence prostate cancer susceptibility in Japanese men. Tumour
Biol. Nov 8–2013.(Epub ahead of print).
|
|
34
|
Lu J, Li XF, Kong LX, Ma L, Liao SH and
Jiang CY: Expression and significance of cyclooxygenase-2 mRNA in
benign and malignant ascites. World J Gastroenterol. 19:6883–6887.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vaisanen MR, Vaisanen T, Jukkola-Vuorinen
A, Vuopala KS, Desmond R, Selander KS and Vaarala MH: Expression of
Toll-like receptor-9 is increased in poorly differentiated prostate
tumors. Prostate. 70:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kauppila JH, Takala H, Selander KS,
Lehenkari PP, Saarnio J and Karttunen TJ: Increased Toll-like
receptor 9 expression indicates adverse prognosis in esophageal
adenocarcinoma. Histopathology. 59:643–649. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Heikki T, Kauppila JH, Soini Y, Selander
KS, Vuopala KS, Lehenkari PP, Saarnio J and Karttunen TJ: Toll-like
receptor 9 is a novel biomarker for esophageal squamous cell
dysplasia and squamous cell carcinoma progression. J Innate Immun.
3:631–638. 2011. View Article : Google Scholar : PubMed/NCBI
|
